Puma Biotechnology (PBYI) News Today $2.84 +0.10 (+3.65%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Puma Biotechnology initiates ALISertib in CAncer trialNovember 20 at 7:46 PM | markets.businessinsider.comBuy Rating Reiterated for Puma Biotechnology Amid Promising Phase 2 Trial and Strategic FDA EngagementNovember 20 at 7:46 PM | markets.businessinsider.comLos Angeles Capital Management LLC Acquires Shares of 245,695 Puma Biotechnology, Inc. (NASDAQ:PBYI)Los Angeles Capital Management LLC purchased a new stake in Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 245,695 shares of the biopharmaceutical companyNovember 17, 2024 | marketbeat.comPuma Biotechnology Inc (PBYI) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic ...November 8, 2024 | finance.yahoo.comPuma Biotechnology Reports Strong Q3 2024 GrowthNovember 8, 2024 | markets.businessinsider.comBarclays Reaffirms Their Sell Rating on Puma Biotechnology (PBYI)November 8, 2024 | markets.businessinsider.comHC Wainwright Reaffirms Buy Rating for Puma Biotechnology (NASDAQ:PBYI)HC Wainwright restated a "buy" rating and issued a $7.00 target price on shares of Puma Biotechnology in a research note on Friday.November 8, 2024 | marketbeat.comQ3 2024 Puma Biotechnology Inc Earnings Call TranscriptNovember 8, 2024 | gurufocus.comPuma Biotechnology, Inc. (PBYI) Q3 2024 Earnings Conference Call TranscriptNovember 8, 2024 | seekingalpha.comPuma Biotechnology (NASDAQ:PBYI) Stock Rating Upgraded by StockNews.comStockNews.com raised Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research report on Friday.November 1, 2024 | marketbeat.comPuma Biotechnology (PBYI) Set to Announce Earnings on ThursdayPuma Biotechnology (NASDAQ:PBYI) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=335006)October 31, 2024 | marketbeat.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Puma Biotechnology, Inc. (NASDAQ: PBYI) and Encourages Investors to Contact the FirmOctober 29, 2024 | globenewswire.comPuma Biotechnology to Host Conference Call to Discuss Third Quarter Financial ResultsOctober 25, 2024 | finance.yahoo.comPuma Biotechnology (NASDAQ:PBYI) Rating Increased to Strong-Buy at StockNews.comStockNews.com upgraded Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research note on Wednesday.October 23, 2024 | marketbeat.comZacks Research Has Positive Outlook for PBYI FY2026 EarningsPuma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Stock analysts at Zacks Research upped their FY2026 earnings per share (EPS) estimates for Puma Biotechnology in a research note issued on Thursday, October 17th. Zacks Research analyst R. Department now anticipates that the biopharmaceuticalOctober 21, 2024 | marketbeat.comPuma Biotechnology IncOctober 18, 2024 | money.usnews.comQ3 EPS Estimate for Puma Biotechnology Increased by AnalystPuma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Analysts at Zacks Research lifted their Q3 2026 earnings per share estimates for Puma Biotechnology in a research note issued on Thursday, October 17th. Zacks Research analyst R. Department now expects that the biopharmaceutical company willOctober 18, 2024 | marketbeat.comZacks Research Analysts Reduce Earnings Estimates for Puma Biotechnology, Inc. (NASDAQ:PBYI)Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Equities researchers at Zacks Research reduced their FY2025 earnings per share (EPS) estimates for Puma Biotechnology in a research note issued on Thursday, September 26th. Zacks Research analyst R. Department now anticipates that the biopharSeptember 30, 2024 | marketbeat.comFrazier Life Sciences Management L.P. Purchases 246,264 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)Frazier Life Sciences Management L.P. lifted its position in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 8.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor ownedSeptember 29, 2024 | marketbeat.comAffinity Asset Advisors LLC Purchases Shares of 250,000 Puma Biotechnology, Inc. (NASDAQ:PBYI)Affinity Asset Advisors LLC purchased a new stake in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 250,000 shares of the biopharmaceutical company's stock,September 25, 2024 | marketbeat.comPuma Biotechnology Inc (PBYI)September 18, 2024 | investing.comPuma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | finance.yahoo.comZacks Research Weighs in on Puma Biotechnology, Inc.'s Q1 2026 Earnings (NASDAQ:PBYI)Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Equities researchers at Zacks Research increased their Q1 2026 earnings per share estimates for shares of Puma Biotechnology in a research note issued to investors on Wednesday, August 28th. Zacks Research analyst R. Department now forecastsSeptember 2, 2024 | marketbeat.comThe Future of Medicine: Key Biotech Stocks to WatchAugust 21, 2024 | theglobeandmail.comThe Future of Medicine: Key Biotech Stocks to Watch (OSTX, CRBP, PBYI, ATNM)August 21, 2024 | theglobeandmail.comPuma Biotech confirms court ruling on patent invalidity, disagrees with verdictAugust 15, 2024 | msn.comMichael Patrick Miller Sells 23,358 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) StockAugust 15, 2024 | insidertrades.comPuma Biotechnology quickly drops after patents for Tagrisso ruled invalidAugust 14, 2024 | msn.comPuma Biotech drops after patents ruled invalid in fight with AstraZeneca over TagrissoAugust 14, 2024 | msn.comPuma Biotechnology, Inc. (NASDAQ:PBYI) Director Sells $81,519.42 in StockPuma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Michael Patrick Miller sold 23,358 shares of the company's stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $3.49, for a total value of $81,519.42. Following the sale, the director now owns 47,000 shares in the company, valued at $164,030. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.August 13, 2024 | marketbeat.comPuma Biotechnology (NASDAQ:PBYI) Rating Lowered to Buy at StockNews.comStockNews.com cut shares of Puma Biotechnology from a "strong-buy" rating to a "buy" rating in a report on Tuesday.August 13, 2024 | marketbeat.comVanguard Group Inc. Reduces Holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI)Vanguard Group Inc. lowered its holdings in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 8.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,491,249 shares of the biopharmaceuticalAugust 12, 2024 | marketbeat.comPuma Biotechnology's (NASDAQ:PBYI) Earnings Offer More Than Meets The EyeAugust 9, 2024 | finance.yahoo.comPuma Biotechnology (NASDAQ:PBYI) Upgraded by StockNews.com to "Strong-Buy"StockNews.com upgraded shares of Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a report on Monday.August 5, 2024 | marketbeat.comAnalysts Have Been Trimming Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target After Its Latest ReportAugust 3, 2024 | finance.yahoo.comPuma Biotechnology (NASDAQ:PBYI) Releases Earnings Results, Beats Estimates By $0.01 EPSPuma Biotechnology (NASDAQ:PBYI - Get Free Report) released its earnings results on Thursday. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.01. Puma Biotechnology had a return on equity of 35.49% and a net margin of 6.79%. The firm had revenue of $47.10 million for the quarter, compared to analyst estimates of $43.99 million. During the same quarter last year, the firm posted $0.05 EPS.August 2, 2024 | marketbeat.comPuma Biotechnology's (PBYI) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $7.00 price objective on shares of Puma Biotechnology in a research report on Friday.August 2, 2024 | marketbeat.comPuma Biotechnology: Hold Rating Justified by Sales Concerns and Financial StrainAugust 2, 2024 | markets.businessinsider.comQ2 2024 Puma Biotechnology Inc Earnings Call TranscriptAugust 2, 2024 | gurufocus.comPuma Biotechnology Reports Second Quarter Financial ResultsAugust 1, 2024 | businesswire.comWhere Puma Biotechnology Stands With AnalystsJuly 26, 2024 | benzinga.comPuma Biotechnology (NASDAQ:PBYI) Given Buy Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $7.00 price objective on shares of Puma Biotechnology in a research note on Friday.July 26, 2024 | marketbeat.comPuma Biotechnology (PBYI) Scheduled to Post Quarterly Earnings on ThursdayPuma Biotechnology (NASDAQ:PBYI) will be releasing earnings after the market closes on Thursday, August 1, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=610403)July 25, 2024 | marketbeat.comMaximo F. Nougues Sells 4,156 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) StockJuly 20, 2024 | insidertrades.comPuma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial ResultsJuly 18, 2024 | businesswire.comInsider Selling: Puma Biotechnology, Inc. (NASDAQ:PBYI) CFO Sells 5,295 Shares of StockJuly 3, 2024 | insidertrades.comPuma Biotechnology, Inc. (NASDAQ:PBYI) CFO Sells $17,314.65 in StockPuma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) CFO Maximo F. Nougues sold 5,295 shares of Puma Biotechnology stock in a transaction on Tuesday, July 2nd. The shares were sold at an average price of $3.27, for a total transaction of $17,314.65. Following the completion of the sale, the chief financial officer now directly owns 166,678 shares of the company's stock, valued at approximately $545,037.06. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.July 2, 2024 | marketbeat.comPuma Biotechnology (NASDAQ:PBYI) Shares Cross Below 200 Day Moving Average of $4.83Puma Biotechnology (NASDAQ:PBYI) Stock Price Crosses Below Two Hundred Day Moving Average of $4.83June 25, 2024 | marketbeat.comPuma Biotechnology, Inc. (NASDAQ:PBYI) Director Sells $89,910.00 in StockJune 18, 2024 | insidertrades.comPuma Biotechnology, Inc. (NASDAQ:PBYI) Director Troy Edward Wilson Sells 27,000 SharesPuma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Troy Edward Wilson sold 27,000 shares of the company's stock in a transaction dated Thursday, June 13th. The shares were sold at an average price of $3.33, for a total value of $89,910.00. Following the sale, the director now owns 350 shares in the company, valued at $1,165.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.June 17, 2024 | marketbeat.com Get Puma Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter. Email Address Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development… YES, I WANT THE #1 CRYPTO NOW PBYI Media Mentions By Week PBYI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PBYI News Sentiment▼1.670.45▲Average Medical News Sentiment PBYI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PBYI Articles This Week▼42▲PBYI Articles Average Week Get Puma Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RAPT Therapeutics News Today Marinus Pharmaceuticals News Today UroGen Pharma News Today Humacyte News Today Annexon News Today Astria Therapeutics News Today Corvus Pharmaceuticals News Today Organogenesis News Today PureTech Health News Today Monte Rosa Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PBYI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Puma Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Puma Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
